Pathology: mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive;
mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | |||||||
IMpassion-130 (all population), 2018 | IMpassion-131 (all population), 2020 | KEYNOTE-355 (all population), 2020 | IMpassion-130 (PDL1>1%), 2018 | IMpassion-131 (PD-L1 > 1%), 2020 | KEYNOTE-355 (CPS>1), 2020 | KEYNOTE-355 (CPS>10), 2020 | ||
pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||||
atezolizumab plus paclitaxel | 2 | T1 | T1 | |||||
atezolizumab plus nab-paclitaxel | 2 | T1 | T1 | |||||
placebo plus SoC | 0 | T0 | T0 | T0 | ||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 |